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ABSTRACT
Background Despite treatment according to the 
current management recommendations, a significant 
proportion of patients with rheumatoid arthritis (RA) 
remain symptomatic. These patients can be considered to 
have ’difficult- to- treat RA’. However, uniform terminology 
and an appropriate definition are lacking.
Objective The Task Force in charge of the 
“Development of EULAR recommendations for the 
comprehensive management of difficult- to- treat 
rheumatoid arthritis” aims to create recommendations 
for this underserved patient group. Herein, we present 
the definition of difficult- to- treat RA, as the first step.
Methods The Steering Committee drafted a definition 
with suggested terminology based on an international 
survey among rheumatologists. This was discussed and 
amended by the Task Force, including rheumatologists, 
nurses, health professionals and patients, at a face- to- 
face meeting until sufficient agreement was reached 
(assessed through voting).
Results The following three criteria were agreed by 
all Task Force members as mandatory elements of the 
definition of difficult- to- treat RA: (1) Treatment according 
to European League Against Rheumatism (EULAR) 
recommendation and failure of ≥2 biological disease- 
modifying antirheumatic drugs (DMARDs)/targeted 
synthetic DMARDs (with different mechanisms of action) 
after failing conventional synthetic DMARD therapy 
(unless contraindicated); (2) presence of at least one of 
the following: at least moderate disease activity; signs 
and/or symptoms suggestive of active disease; inability 
to taper glucocorticoid treatment; rapid radiographic 
progression; RA symptoms that are causing a reduction 
in quality of life; and (3) the management of signs 
and/or symptoms is perceived as problematic by the 
rheumatologist and/or the patient.
Conclusions The proposed EULAR definition for 
difficult- to- treat RA can be used in clinical practice, 
clinical trials and can form a basis for future research.
INTRODUCTION
European League Against Rheumatism (EULAR) 
recommendations provide valuable guidance to 
direct the management of rheumatoid arthritis 
(RA). The treat- to- target (T2T) strategy advises an 
agreed disease activity target, remission or at least 
low disease activity, that can in turn inform respon-
sive treatment escalation.1–3 However, a number of 
patients remain symptomatic despite recommended 
treatment changes reflecting the complex interplay 
of disease and wider patient and clinical factors 
that leads to the increasingly recognised term of 
‘difficult- to- treat RA’.4–7
A recent international survey of rheumatologists 
highlighted the perceived management problems 
and features in this patient category; the results of 
which confirmed the unmet need of this subpopu-
lation of RA patients.8 The survey indicated that in 
addition to new drugs, new management approaches 
are also needed for the optimal treatment of these 
patients. Consequently, a EULAR Task Force was 
established to derive comprehensive recommenda-
tions addressing unmet needs in the management of 
difficult- to- treat (D2T) RA. Uniform terminology 
and a clear definition for this patient group are 
lacking. In the current literature, different terms are 
used to describe this subpopulation of RA patients, 
for example, severe, refractory, resistant to multiple 
drugs or treatments, established and difficult- to- 
treat.4–7 As an initial step in the development of 
the management recommendations for D2T RA, 
terminology and a definition of this complicated 
RA patient group was established by the Task Force, 
guided by the results of the survey.8
METHODS
Steering committee and task force
The Steering Committee of the Task Force included 
a convenor (GN), co- convenor (JMvL), two meth-
odologists (PMJW and DvdH) a rheumatology 
postdoctoral fellow (MJHdH) and three fellows 
(NMTR, MK and AH). The Task Force comprises 
32 individuals (including the Steering Committee 
members) of which 25 members were present at the 
first Task Force meeting, which took place in August 
2018. Among the Task Force members, there were 
26 rheumatologists (including two EMerging EUlar 
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Network (EMEUNET) representatives), two patient partners, 
one health professional, one psychologist, one pharmacist and 
one occupational therapist. All rheumatologists are experienced 
in the treatment of RA, the majority with significant experi-
ence in clinical trials and a proportion in outcomes research. 
Numerous Task Force members have a leading role in organ-
ising and evaluating patient registries. All Task Force members 
declared their potential conflicts of interest before the start of 
the project.
Survey
An online survey was conducted among rheumatologists to iden-
tify characteristics of D2T RA; the survey was distributed by 
email via the authors’ networks and by EMEUNET. The survey 
consisted of nine questions, including two general questions 
‘Where do you work? How many RA patients do you treat?’, 
and four multiple- choice and three open questions regarding 
the definition of D2T RA. Four hundred and ten respondents 
from 33 countries completed the survey between July 2017 and 
March 2018, 96% of the respondents were European.8
Development of terminology and definition for D2T RA
The Steering Committee created the first draft of the definition 
based on the results of the survey and on a scoping literature 
search that was performed to explore different definitions that 
currently have been used (by NMTR, MJHdH and PMJW, see, 
online supplemental material 1). The results of the survey, the 
proposed terminology and the draft definition were presented 
to the Task Force at the first Task Force meeting. The definition 
was divided into three parts: treatment failure history, charac-
terisation of active/symptomatic disease and clinical perception.
Agreement process
After the presentation of the draft terminology and definition, 
the general concepts were discussed and amended. Thereafter, 
the detailed wording was discussed and amended until consensus 
was reached. A voting process was conducted for each item 
of the terminology and definition. In case no consensus was 
reached among the present Task Force members, the preferred 
version was selected by voting. Twenty- one Task Force members 
were present during this discussion and voting process. After the 
meeting, two versions of the definition were distributed among 
all Task Force members to select the final version.
RESULTS
Terminology
At the first Task Force meeting, based on a scoping literature 
search and the suggestions of the Task Force members a variety 
of potential terms to describe this patient population were 
presented, including severe, refractory, multidrug/treatment 
resistant and complex RA. None of these terms was deemed to 
cover the wide range of possible clinical scenarios which may 
be relevant for this patient population. Since ‘difficult- to- treat’ 
is a widely accepted term in several fields including pulmon-
ology, psychiatry and cardiology9–11 this terminology was finally 
proposed by the Steering Committee and unanimously endorsed 
by the Task Force (21/21 agreed by voting).
Definition
Thereafter, we sought to create a definition of D2T RA based 
on the results of the previously mentioned international survey8 
and expert opinions. The Task Force agreed that both articular 
and extra- articular components should be considered and agreed 
to include the following criteria in the definition: (1) treat-
ment failure history; (2) characterisation of active/symptomatic 
disease; and (3) clinical perception. All three criteria need to be 
present to confirm the state of D2T RA.
Criterion #1: treatment failure history
In the survey, 48% of the respondents selected ‘≥2 conventional 
synthetic disease- modifying antirheumatic drugs (csDMARDs) 
AND ≥2 biological (b)DMARDs or targeted synthetic (ts)
DMARDs with different mode of action’ for the number and type 
of antirheumatic drugs that should have failed before a patient 
can be considered to have D2T RA. The Steering Committee 
initially proposed to include treatment duration in the definition 
‘Treatment according to the current standard of care/EULAR 
recommendations for ≥1 year’. This was chosen so that D2T RA 
patients are in phase III of the current RA management recom-
mendations, in which no recommendation is given other than to 
switch to another b/tsDMARD.1 However, inclusion of a certain 
time period in the definition was not supported by all Task Force 
members (primarily in order to provide flexibility) and the Task 
Force voted against referral to a treatment duration period for 
the definition of D2T RA (19/21 agreed, 2 abstained).
All Task Force members agreed to include the number of 
DMARDs previously failed in the definition and to create the 
definition consistent with the current EULAR RA management 
recommendations. ‘Failure of at least two b/tsDMARDs with 
different mode of action’ was selected by the majority of the 
respondents of the survey.8 Although according to the current 
EULAR recommendations1 no prioritisation for switching mech-
anism of action versus cycling is stated, it was decided that before 
being classified as D2T RA, a patient should at least have failed 
two b/tsDMARDs with different mechanisms of action. Conse-
quently, it was decided to select this cut- off by the Task Force. 
With this cut- off, patients had to have completed phase III of 
the recommendations at least once (ie, they may also have been 
treated with multiple bDMARDs of a single class (eg, several 
tumour necrosis factor inhibitors) and also have failed another 
b/tsDMARD). Finally, all members agreed to select the following 
proposal: ‘Treatment according to EULAR recommendation 
and failure of ≥2 b/tsDMARDs with different mechanisms of 
action after failing csDMARD therapy (unless contraindicated)’ 
(21/21 agreed). This also indicates that if csDMARD treatment 
is contraindicated, failure of ≥2 b/tsDMARDs with different 
mechanisms of action is sufficient.
Socioeconomic factors may limit the access to expensive 
DMARDS (eg, in low income countries), therefore (with the 
agreement of all Task Force members) we have added to the first 
criterion: ‘unless restricted by access to treatment due to socio-
economic factors’.
Criterion #2: characterisation of active/symptomatic disease
Fifty per cent of the respondents of the international survey 
selected ‘disease activity score assessing 28 joints using eryth-
rocyte sedimentation rate (DAS28- ESR)>3.2 OR presence of 
signs suggestive of active inflammatory disease activity with a 
DAS28- ESR≤3.2’ as a characteristic of D2T RA. Additionally, 
95% of the respondents of the international survey suggested to 
include the inability to taper glucocorticoids (GCs) in the criteria 
of D2T.8 Therefore, the Steering Committee proposed the 
following characterisation of active/symptomatic disease: ‘Pres-
ence of active disease defined as ≥1 of: (1) DAS28- ESR>3.2; 
(2) Presence of signs suggestive of active RA; and/or (3) Inability 
to taper oral glucocorticoids (below 7.5 mg/day prednisone or 
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equivalent)’. At the Task Force meeting, it was decided to include 
not only DAS28, which was the only composite disease activity 
measure offered in the survey, but to rather use a more generic 
definition: ‘at least moderate disease activity (according to vali-
dated composite measures including joint counts, for example, 
DAS28- ESR>3.2 or clinical disease activity index (CDAI)>10)’ 
(21/21 agreed). In addition to clinical signs and symptoms, it 
was agreed that this clarification should also include imaging and 
biochemical markers suggestive of active disease.
Furthermore, all Task Force members agreed that not only 
patients with joint- related problems should qualify to be defined 
as being D2T. Extra- articular manifestations, such as vasculitis, 
pericarditis, scleritis or glomerulonephritis may complicate the 
management of RA, and were therefore decided to be included 
in the definition. This resulted in the following wording: ‘Signs 
(including acute phase reactants and imaging) and/or symp-
toms suggestive of active disease (joint related or other)’ (21/21 
agreed).
In the survey, 43% of the respondents selected to include 
‘unable to taper glucocorticoids below 5 mg prednisone or 
equivalent daily’ and 46% selected ‘unable to taper glucocorti-
coids below 10 mg prednisone or equivalent daily’ (in addition, 
another 6% chose to include inability to taper GCs, although 
with a different, unspecified dose).8 At the Task Force meeting, 
it was decided to include the following definition as a compro-
mise: ‘Inability to taper oral glucocorticoids (below 7.5 mg/day 
prednisone or equivalent)’. The Task Force voted to keep this 
item in the definition (19/21 agreed).
During the Task Force meeting, additional possible signs of 
active disease were explicitly suggested for inclusion in the defi-
nition. First, the Task Force agreed to include rapid radiographic 
progression in the definition as a possible feature of D2T RA, as 
this might be occasionally observed even in case of clinically inac-
tive disease. The following was proposed: ‘Rapid radiographic 
progression (with or without signs of active disease)’ (21/21 
agreed). Second, non- inflammatory disease was considered, since 
these complaints, for example, concomitant fibromyalgia, might 
mimic inflammatory activity. Non- inflammatory disease may 
lead to several aforementioned characteristics of active/symp-
tomatic disease. Furthermore, non- inflammatory disease might 
also lead to other clinically important complaints. Therefore, to 
ensure that patients with non- inflammatory complaints could be 
classified as having difficult- to- treat RA, it was suggested and 
unanimously agreed to add ‘Well- controlled disease according to 
above standards, but still having RA symptoms that are causing a 
reduction in quality of life’ (21/21 agreed).
The Task Force discussed whether to add fatigue to the defi-
nition, as this is one of the most common problems.12 13 Since 
fatigue can diminish quality of life, it was suggested to be already 
included in the definition. In accordance with the survey (58% 
of respondents suggested not to include fatigue),8 all Task Force 
members agreed to leave out the explicit mentioning of fatigue 
from the definition of D2T RA (21/21 agreed).
Criterion #3: clinical perception
As a final criterion, the Steering Committee suggested to include 
‘The disease is perceived as problematic by the rheumatologist 
and/or the patient’. This suggests that only clinical scenarios 
which are judged as problematic (eg, apparently ineffective 
treatment) are referred to as D2T RA. Since the definition is 
only applicable to patients in which a management problem 
is present, it was agreed to adapt the definition accordingly: 
‘The management of signs and/or symptoms is perceived as 
problematic by the rheumatologist and/or the patient’. There 
were some concerns that this criterion might be too subjective, 
especially for research. However, the focus of the recommen-
dations should be on the clinical implications, which supports 
to include this criterion. All Task Force members agreed unani-
mously on this (21/21 agreed).
Order
Most Task Force members agreed to start the definition with the 
treatment failure history criterion instead of the characterisation 
of active/symptomatic disease. However, the group noted that 
starting with signs of active disease might be better focussed on 
the patients’ needs. Therefore, with the agreement of all Task 
Force members, it was decided to vote on the order of the two 
criteria, by which all Task Force members supported the first 
version of the definition (agreed 31/31 (AH, who joined the Task 
Force later, did not vote), box 1).
DISCUSSION
The treatment of the heterogeneous patient population that 
comprises D2T RA is often a clinical challenge for which prac-
tical management recommendations are needed. Several factors 
may complicate the management of these patients. Such factors 
include persistent inflammatory activity due to resistance of 
disease to DMARDs, limited drug options due to adverse drug 
reactions and/or comorbidities that preclude the use of DMARDs 
or treatment non- adherence. On the other hand, concomitant 
Box 1 EULAR definition of difficult- to- treat RA
1. Treatment according to European League Against 
Rheumatism recommendation and failure of ≥2 b/tsDMARDs 
(with different mechanisms of action)* after failing csDMARD 
therapy (unless contraindicated).†
2. Signs suggestive of active/progressive disease, defined as ≥1 
of:
a. At least moderate disease activity (according to validated 
composite measures including joint counts, for example, 
DAS28- ESR>3.2 or CDAI>10).
b. Signs (including acute phase reactants and imaging) and/
or symptoms suggestive of active disease (joint related or 
other).
c. Inability to taper glucocorticoid treatment (below 7.5 mg/
day prednisone or equivalent).
d. Rapid radiographic progression (with or without signs of 
active disease).‡
e. Well- controlled disease according to above standards, but 
still having RA symptoms that are causing a reduction in 
quality of life.
3. The management of signs and/or symptoms is perceived as 
problematic by the rheumatologist and/or the patient.
All three criteria need to be present in D2T RA.
b, biological; CDAI, clinical disease activity index; cs, conventional 
synthetic; DAS28- ESR, disease activity score assessing 28 joints 
using erythrocyte sedimentation rate; DMARD, disease- modifying 
antirheumatic drug; mg, milligram; RA, rheumatoid arthritis; ts, targeted 
synthetic.
*Unless restricted by access to treatment due to socioeconomic factors.
†If csDMARD treatment is contraindicated, failure of ≥2 b/tsDMARDs 
with different mechanisms of action is sufficient.
‡Rapid radiographic progression: change in van der Heijde- modified 
Sharp score ≥5 points at 1 year.16
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syndromes or diseases, such as fibromyalgia, osteoarthritis and 
psychosocial factors associated with poor coping, can result in 
non- inflammatory symptoms (eg, pain) that can mimic inflam-
matory activity and therewith contribute to D2T RA. Currently, 
D2T RA EULAR management recommendations are under devel-
opment, aiming to cover all inflammatory and non- inflammatory 
factors underlying D2T RA. These will include both pharmaco-
logical and non- pharmacological treatment options and will be 
complementary to the existing RA recommendations.1–3 As an 
essential initial step in the development of recommendations for 
D2T RA, the Task Force provided terminology and a definition 
of D2T RA.
The term ‘difficult- to- treat’ was selected because it was deemed 
to best capture the possible clinical scenarios. A definition of 
D2T RA, consisting of three criteria was agreed on by consensus 
by a multidisciplinary group of experts including patient repre-
sentatives: (1) treatment failure history; (2) characterisation of 
active/symptomatic disease; and (3) clinical perception. These 
elements were selected based on the results of the survey.
The second criterion has five subelements, reflecting all 
potential clinically meaningful indicators of active/symptomatic 
disease. In this definition, in accordance with recent recommen-
dations, the term ‘moderate disease activity according to vali-
dated composite measures including joint counts’ was used.1 3 
However, these indices might not always include the affected 
joints (eg, feet) or other signs of disease activity.14 The ‘Signs 
(including acute phase reactants and imaging) and/or symp-
toms suggestive of active disease (joint related or other)’ item 
covers all potentially affected joints, as well as extra- articular 
manifestations.
The acceptable GC dose for chronic use remains a matter of 
discussion, although there is a significant group of RA patients 
that is treated with GCs long- term. Current EULAR RA recom-
mendations suggest to consider using GCs, when initiating or 
changing csDMARDs, but GCs should be tapered as rapidly as 
clinically feasible.1 The EULAR Task Force in charge of evalu-
ating the risk of long- term GC therapy suggested that the risk 
of harm is generally low at long- term doses of ≤5 mg predni-
sone equivalent per day.15 In the currently proposed definition of 
D2T RA, in accordance with the result of the survey,8 ‘Inability 
to taper glucocorticoid treatment (below 7.5 mg/day prednisone 
or equivalent)’ is listed as a criterion. We realise that lower GC 
doses were suggested by other EULAR Task Forces, on the other 
hand, we believe that less stringent criteria will be more realistic 
to define the D2T patients, as inability to follow these criteria 
can indicate a management problem.
The Task Force felt that not only patients fulfilling criterion 1 
and 3 with inflammatory activity should be able to be classified as 
having D2T RA, but also those patients with non- inflammatory 
complaints. Coexisting non- inflammatory conditions may 
lead to a high clinical burden. These may mimic inflammatory 
activity by hampering proper grading of disease activity and 
‘falsely’ elevating disease activity scores through rather subjec-
tive measures.5 Additionally, these symptoms (such as fatigue or 
pain) could reduce quality of life. Therefore, the second crite-
rion ‘Signs suggestive of active/progressive disease’ was deemed 
to cover the wide variety of patients with inflammatory activity 
and/or non- inflammatory complaints.
There are some limitations of this work. The definition 
of D2T RA needs to be validated. Rheumatologists’ and 
patients’ acceptance can, as a first step, be used as a sign of 
face validity. Furthermore, not all aspects of D2T RA may 
have been adequately captured by the currently proposed 
definition, although the criteria mentioned are agreed on by 
a large group of experts based on a survey involving >400 
rheumatologists. A further complicating factor might be that, 
as also apparent from the definition, this patient group is 
rather heterogeneous and hence difficult to capture in one 
definition.
In conclusion, the principal goal of RA management is to 
achieve sustained remission or at least low disease activity 
following steps of the current EULAR recommendations.1 A 
new management approach is necessary for D2T RA patients, 
in which this treatment goal is not achieved. Hopefully, the 
definition presented here will provide a robust and consis-
tent identification of patients with D2T RA. In addition, this 
definition can provide a platform to define a group of similar 
patients for research. Further work is underway to provide 
detailed recommendations for the management of D2T RA.
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